appliedtherapeutics.com (APLT) Price to Earnings Ratio

Corporate emblem and logo of Applied Therapeutics Inc. (APLT)

The Applied Therapeutics (APLT) price chart demonstrates the dynamics of an asset with a value of -0.80. The business is susceptible to the influence of global conflicts, which hinder raw material procurement and the protection of intellectual property rights. Management aims to ensure high-quality research to obtain marketing authorizations for its drugs. The current strategic vector is shifted toward launching new products in the US and European markets.

appliedtherapeutics.com (APLT) Price to Earnings Ratio: for the period 07/04/2022 - 02/16/2026

Comprehensive metric breakdowns and analytics for Applied Therapeutics (APLT)

- price and consensus price forecast:
Stock Price Applied Therapeutics Inc.|APLT - Price Target Chart
- market capitalization details:
Market Value Applied Therapeutics, Inc.|APLT - Enterprise Value
- book capitalization information:
Net Assets per Share Applied Therapeutics|APLT - Company Net Assets|Market Capitalization to Net Assets appliedtherapeutics.com|APLT - Company Total Assets
- debt and solvency information:
Debt to Capital Applied Therapeutics|APLT - Long-Term Debt to Capital|Short-Term Debt to Capital Ratio appliedtherapeutics.com|APLT - Company Total Debt|Debt to Net Assets Ratio Applied Therapeutics, Inc.|APLT - Company Long-Term Debt|Current Liabilities Applied Therapeutics|Intermediate Coverage Ratio appliedtherapeutics.com
- earnings and market multiples details:
APLT - Net Profit|Projected Future Earnings Applied Therapeutics|APLT - Price to Earnings Ratio|Future Price to Earnings Multiple Applied Therapeutics Inc.|APLT - Price/Earnings to Growth Ratio|Enterprise Value to EBITDA Ratio Applied Therapeutics, Inc.|APLT - Operating profit EBITDA|Net earnings per share (EPS TTM) Applied Therapeutics|APLT - Net earnings per share (EPS TTM)|Quarterly EPS earnings growth appliedtherapeutics.com|APLT - Earnings per share growth in current year|Net earnings per share change forecast for next year Applied Therapeutics
General company analysis:Applied Therapeutics Inc. - APLT
Original product of Applied Therapeutics Inc.

For Applied Therapeutics (APLT), which specializes in developing small molecules for rare metabolic pathologies using external CDMO facilities, this indicator determines the market value of each unit of net profit. An analysis of the P/E ratio allows current quotes to be correlated with actual earnings, separating speculative noise from the business's fundamental value and identifying risks of capital freeze or asset overvaluation.

Analysis of competing companies

P/E Multiple vrtx.com|Price to Earnings Ratio Alnylam (ALNY)|Price to Earnings Ratio INSM (Insmed Inc.)|P/E Multiple UTHR (United Therapeutics Corp.)|Business Payback Period BioMarin Corp (BMRN)|BBIO: Price to Earnings Ratio|Market Cap to Net Income BGM|COGT: P/E Multiple|Market Cap to Earnings Xeris Biopharma Holdings, Inc. (XERS)|KROS (Keros Pharma) - P/E Multiple|Price to Earnings Multiple ARCT (Arcturus Corp)|Price to Earnings Ratio ETON (Eton Pharmaceuticals)|KMDA (kamada.com) - Company Value to Net Income|Price to Earnings Ratio Fulcrum Therapeutics, Inc. FULC|ABEO (Abeona Therapeutics, Inc.) - Market Cap to Net Income|Mereo BioPharma Group PLC - P/E Multiple|Company Value to Net Income PLX (Protalix BioTherapeutics, Inc)|PLRX: P/E Multiple|aileronrx.com (RNTX) - P/E Multiple|Price to Earnings Ratio Gelteq Ltd|AYTU: Company Value to Net Income|Price to Earnings Ratio Chemomab Therapeutics (CMMB)|Price to Earnings Ratio srxhealth.com SRXH|P/E Multiple PLRZ (Polyrizon)|P/E Multiple Aeterna Zentaris Inc AEZS|Cyclo Therapeutics, Inc. - P/E Multiple|INZY - P/E Multiple|Reneo Pharma (RPHM) - Price to Earnings Ratio|Market Cap to Net Income CSCI (COSCIENS Bio)